Apixaban (Eliquis) Manufacturing Plant Project Report 2025: Manufacturing Plant Setup and Operations

Business Feb 12, 2025 4 Add to Reading List

Introduction

Apixaban, commonly known by its brand name Eliquis, is an oral anticoagulant used primarily in the prevention and treatment of blood clots, including conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke prevention in patients with atrial fibrillation. Apixaban works by inhibiting Factor Xa, a crucial enzyme in the coagulation cascade, preventing the formation of blood clots. Manufactured by Bristol-Myers Squibb and Pfizer, Eliquis has become one of the most prescribed anticoagulants worldwide due to its efficacy, safety profile, and ease of use. Given the growing demand for cardiovascular medications and the increasing aging population, setting up an Apixaban (Eliquis) Manufacturing Plant presents a significant business opportunity. This Apixaban (Eliquis) Manufacturing Plant Project Report outlines the steps involved in establishing a production facility for Apixaban, covering market analysis, raw materials, manufacturing processes, equipment, plant layout, and financial considerations.

Market Overview

The global market for anticoagulants, including Apixaban, is growing rapidly due to an increase in cardiovascular diseases, an aging population, and a greater focus on blood clot prevention. Here are key factors contributing to the rising demand:

Prevalence of Cardiovascular Diseases: A growing number of people are suffering from cardiovascular conditions like atrial fibrillation, heart failure, and venous thromboembolism. The demand for drugs like Apixaban is directly tied to the prevalence of these diseases.
Aging Population: As the global population ages, the number of individuals at risk of stroke, heart attacks, and other clot-related conditions increases. Elderly individuals are particularly prone to atrial fibrillation and other clotting disorders, fueling demand for Apixaban.
Increased Awareness of Stroke Prevention: Public health campaigns aimed at reducing the incidence of stroke and related complications have raised awareness about the need for effective anticoagulants. Apixaban is preferred by many healthcare providers due to its favorable safety profile and once-daily dosing.
Competitive Pricing and Efficacy: Apixaban is often seen as an effective alternative to older anticoagulants such as warfarin. Its advantages, such as no need for regular blood monitoring, have contributed to its increasing market share.
Rising Healthcare Expenditures: In both developed and developing economies, governments and private healthcare providers are increasing their budgets for pharmaceutical treatments, particularly for chronic conditions like atrial fibrillation and venous thromboembolism.
Generic Versions: As the patent for Apixaban expires in various regions, the market will witness the entry of generic versions, further increasing competition and accessibility.

Get a Free Sample Report with Table of Contents@

https://www.expertmarketresearch.com/prefeasibility-reports/apixaban-eliquis-manufacturing-plant-project-report/requestsample

Raw Materials

The key raw materials required to manufacture Apixaban include:

Active Pharmaceutical Ingredient (API): The core raw material for Apixaban is the active pharmaceutical ingredient, which is synthesized through a complex chemical process. The API is produced through a series of chemical reactions involving various chemicals and reagents.
Excipients: Excipients are substances that aid in the formulation and stabilization of the drug. They include binders, fillers, lubricants, and disintegrants, which help to form tablets or capsules. Common excipients used in pharmaceutical formulations include lactose, microcrystalline cellulose, magnesium stearate, and sodium starch glycolate.
Solvents and Reagents: Various solvents such as ethanol, acetone, and other organic solvents may be used during the synthesis of the API. Reagents such as acids, bases, and catalysts are also required to initiate and control chemical reactions.
Packaging Materials: Packaging materials for the final drug product include blister packs, bottles, and labels. These materials must meet the requirements for drug safety, stability, and regulatory compliance.

Manufacturing Process

The production of Apixaban involves a series of complex chemical reactions followed by formulation, packaging, and quality control processes. Below is an overview of the manufacturing process:

Step 1: Synthesis of Active Pharmaceutical Ingredient (API)

The production of Apixaban begins with the synthesis of the active pharmaceutical ingredient (API). The synthesis involves multi-step organic reactions, starting with a suitable precursor molecule. The key steps in the synthesis process include:

Step 1.1 – Chemical Synthesis: The starting material undergoes several chemical reactions, such as nucleophilic substitutions, cyclizations, and reductions, to create the core structure of Apixaban.
Step 1.2 – Purification: After the synthesis, the crude API is purified through various techniques like crystallization, filtration, and chromatography to obtain the desired purity levels for pharmaceutical-grade Apixaban.

Step 2: Formulation

Once the API is prepared, it is blended with excipients to form the final dosage form. The process of formulation includes:

Step 2.1 – Mixing: The API is mixed with excipients such as binders (e.g., microcrystalline cellulose), disintegrants (e.g., sodium starch glycolate), and lubricants (e.g., magnesium stearate) in a controlled manner.
Step 2.2 – Granulation: The mixture is subjected to wet or dry granulation to form granules that can be compressed into tablets. Wet granulation involves adding a binder solution to the powder mixture, while dry granulation involves compacting the powder directly.
Step 2.3 – Compression: The granules are compressed into tablets or filled into capsules, depending on the final product requirements. Compression machines are used to ensure uniform tablet size, weight, and hardness.

Step 3: Coating (If Applicable)

In some cases, Apixaban tablets may be coated to improve stability, ease of swallowing, and appearance. The coating process involves applying a thin layer of material (e.g., hydroxypropyl methylcellulose) over the tablets, which can be done using a coating pan or fluidized bed coater.

Step 4: Drying

After granulation and compression, the tablets are dried to remove any residual moisture. The drying process ensures the tablets are stable and will not degrade over time.

Step 5: Quality Control and Testing

Quality control (QC) is a crucial part of the manufacturing process to ensure that the Apixaban tablets meet the required safety, efficacy, and quality standards. The QC process includes:

Physical Testing: Testing the tablets for weight uniformity, hardness, friability, and dissolution rate.
Chemical Testing: Analyzing the API concentration, excipient content, and the stability of the drug in its final dosage form.
Microbial Testing: Ensuring that the product is free from contamination by harmful microorganisms.
Stability Testing: Testing the product under various environmental conditions to assess its shelf life and stability.

Step 6: Packaging

Once the tablets are manufactured and tested, they are packaged in appropriate materials to protect them from moisture, light, and contamination. The packaging process includes:

Blister Packaging: Tablets are placed in individual cavities of blister packs, ensuring proper sealing to maintain the integrity of each tablet.
Bottling: Tablets may also be placed in bottles with tamper-evident seals to ensure product safety.
Labeling: The final product is labeled with necessary information, including dosage instructions, expiry date, and batch number, in compliance with regulatory requirements.

Equipment Required

To set up an Apixaban (Eliquis) manufacturing plant, the following equipment is required:

Reactor Vessels: For the synthesis of the API through chemical reactions. These vessels are equipped with temperature and pressure controls.
Filtration and Purification Equipment: For separating impurities and purifying the API.
Granulation Equipment: Machines such as high-shear granulators or fluidized bed granulators used for mixing and granulating the raw materials.
Tablet Compression Machines: These machines are used to compress granules into tablets with the desired weight and size.
Coating Machines: For applying the coating to tablets, if required.
Drying Units: Equipment for drying granules and tablets to remove moisture and ensure stability.
Quality Control Lab: A laboratory for conducting physical, chemical, and microbiological tests on the raw materials and finished product.
Packaging Machines: Automated machines for blister packaging, bottling, and labeling.
Storage and Warehousing: Climate-controlled storage facilities for raw materials and finished products.

Plant Layout and Design

The layout of an Apixaban manufacturing plant should optimize workflow, efficiency, and safety. The main areas include:

Raw Material Storage Area: For storing raw materials like solvents, chemicals, and excipients, which must be kept under controlled conditions.
API Synthesis Area: A dedicated space for the chemical synthesis of Apixaban, with reactors and filtration systems.
Formulation Area: Where mixing, granulation, and compression of the API with excipients take place.
Coating and Drying Area: For tablet coating and drying processes.
Quality Control Lab: A lab for testing raw materials and finished products to ensure quality and compliance with regulations.
Packaging Area: For blister packaging, bottling, and labeling of the finished product.
Waste Management Area: To handle the disposal of hazardous chemicals and waste generated during the manufacturing process.

Financial Considerations

The financial requirements for setting up an Apixaban manufacturing plant include:

Initial Investment: The cost of land, plant construction, equipment acquisition, and raw material procurement.
Operating Costs: This includes labor, utilities (water, electricity), maintenance, and raw material costs.
Regulatory Costs: Obtaining necessary approvals, certifications, and maintaining compliance with regulatory authorities like the FDA (U.S.), EMA (EU), and local health agencies.
Revenue: The revenue generated by selling Apixaban tablets or capsules to pharmaceutical distributors, hospitals, and clinics.
Profitability: Profitability will depend on production efficiency, market demand, and pricing strategies. Competitive pricing, coupled with high production standards, will lead to higher market share.

Media Contact

Company Name: Claight Corporation
Contact Person: Lewis Fernandas, Corporate Sales Specialist — U.S.A.
Email: sales@expertmarketresearch.com
Toll Free Number: +1–415–325–5166 | +44–702–402–5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
Aus Site: https://www.expertmarketresearch.com.au